 |
|
|
| |
ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
Massimo Puoti 1, Curti s Cooper2, Mark Sulkowski3, Graham R Foster4, Thomas Berg5, Erica Villa6, Federico Rodriguez-Perez7, Vinod Rustgi8, David Wyles9, Marti n King10, Barbara McGovern10, Heiner Wedemeyer11
1Ospedale Niguarda Ca Granda, Milan, Italy; 2University of Ott awa, Ott awa, Ontario, Canada; 3Johns Hopkins University, Balti more, Maryland, United States; 4Queen Mary University of London, Barts Health, London, United Kingdom; 5Universitätsklinikum Leipzig, Leipzig, Germany;
6AOU Policlinico di Modena, Modena, Italy; 7Gastroenterology and Hepati c Wellness Center, Santurce, Puerto Rico; 8University of Pitt sburgh Medical Center, Pitt sburgh, Pennsylvania, United States; 9University of California at San Diego, La Jolla, California, United States;
10AbbVie Inc., North Chicago, Illinois, United States; 11Medizinische Hochschule Hannover, Hannover, Germany
|
| |
|
|
|
|
|
